Acalculous Cholecystitis in a Patient with Hepatocellular Carcinoma on Sorafenib
Author Information
Author(s): Mariko Sanda, Hideyuki Tamai, Hisanobu Deguchi, Yoshiyuki Mori, Kosaku Moribata, Naoki Shingaki, Kazuki Ueda, Izumi Inoue, Takao Maekita, Mikitaka Iguchi, Kimihiko Yanaoka, Masashi Oka, Masao Ichinose
Primary Institution: Wakayama Medical University
Hypothesis
The study investigates the occurrence of acute acalculous cholecystitis in a patient undergoing sorafenib therapy for hepatocellular carcinoma.
Conclusion
The case suggests a strong causal relationship between sorafenib therapy and the development of acute acalculous cholecystitis.
Supporting Evidence
- The patient had no risk factors for acalculous cholecystitis, suggesting a strong link to sorafenib.
- Imaging showed marked enlargement of the gallbladder without calculi.
- Histological examination revealed chronic cholecystitis and vascular changes in the gallbladder.
Takeaway
A woman taking a cancer drug called sorafenib got a serious gallbladder problem without any stones, which doctors think was caused by the medicine.
Methodology
The patient was treated with sorafenib and underwent imaging and surgical procedures to diagnose and address the gallbladder condition.
Limitations
The study is based on a single case report, limiting the generalizability of the findings.
Participant Demographics
The patient was a 67-year-old woman with compensated cirrhosis type B and hepatocellular carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website